Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.

This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.

Companies announcing executives moves this week include Celgene with a new CFO, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector, Axcella Health, and NDA Group. The British Generic Manufacturers Association also announced a new chair.